Latest news with #KuraOncology
Globe and Mail
6 days ago
- Business
- Globe and Mail
FTase Inhibitor Market Set for Significant Growth Through 2034, Driven by Oncology and Rare Disease Applications
DelveInsight projects strong FTase inhibitors market growth through 2034, led by oncology and rare disease use. Key companies include Sentynl Therapeutics (ZOKINVY), Kura Oncology (tipifarnib), Novartis (alpelisib combos), Eiger BioPharmaceuticals, and AnGes Inc. Advances target progeroid laminopathies, HRAS-mutant HNSCC, and novel indications, with approvals, partnerships, and late-stage trials driving expansion. DelveInsight's ' FTase Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 ' report delivers a comprehensive analysis of the FTase Inhibitor market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Key Takeaways Market size projection: As per DelveInsight's analysis, the total market size of FTase inhibitors in the 7MM is expected to surge significantly by 2034, driven by expanding applications in oncology and rare genetic disorders. Patient population data: The report provides the total FTase inhibitor potential pool, including Progeria cases occurring in approximately 1 in every 4 million live births worldwide and around 900K new head and neck squamous cell carcinoma cases each year. Key companies: Leading FTase inhibitor companies, such as Sentynl Therapeutics (formerly Eiger BioPharmaceuticals), Kura Oncology, and others are profiled. FTase Inhibitors Pipeline assets: Some of the key FTase inhibitor pipeline assets include tipifarnib in HRAS-mutant HNSCC and novel combination regimens with PI3Kα inhibitors. In March 2025, significant study published research on the highly active FTase peptide inhibitor PD083176 (d2,d3,d5) for treating acute liver failure (ALF), demonstrating that this optimized FTase inhibitor could attenuate ALF progression by modulating PANoptosis. Another research puslished in January 2025 demonstrated that lonafarnib (LNF), an approved oral FTase inhibitor, shows promise as an antiviral treatment against SARS-CoV-2. January 2024: ZOKINVY (lonafarnib) secured marketing approval in Japan via Eiger BioPharmaceuticals and partner AnGes Inc. May 2024: Sentynl Therapeutics closed the acquisition of the ZOKINVY program from Eiger BioPharmaceuticals. Discover recent advancements in the FTase Inhibitor landscape @ FTase Inhibitor Recent Developments. FTase Inhibitors Market Dynamics The FTase inhibitors market currently represents a niche yet high-growth segment within targeted therapeutics. As of 2025, the market remains modest in size, primarily anchored by ZOKINVY's orphan-disease indications, but is poised for expansion through oncology applications. FTase Inhibitors market momentum is propelled by validated survival benefits in ultra-rare progeroid laminopathies and emerging data in HRAS-driven cancers. Scientific rationale for FTase inhibition stems from the blockade of protein farnesylation, notably of progerin in HGPS and HRAS in HNSCC, disrupting aberrant cell signaling and proliferation. The FTase Inhibitors clinical development activity is robust, with tipifarnib advancing through Phase II/III trials both as monotherapy and in combination with Novartis's alpelisib. Additional early-stage candidates are exploring synergistic strategies to overcome resistance via dual prenylation pathway targeting. The FTase Inhibitor competitive landscape features established biotech players, with strategic alliances and licensing deals facilitating access to novel mechanisms and patient populations. For example, the Sentynl–AnGes partnership accelerated ZOKINVY's geographic reach, while Kura Oncology's collaborations underpin its oncology pipeline. FTase Inhibitors market barriers include compensatory prenylation pathways (geranylgeranylation) that may attenuate FTase inhibitor efficacy, and the ultra-orphan status limiting commercial scale. However, opportunities abound in biomarker-driven patient selection, combination regimens to deepen responses, and expansion into other RAS-dependent malignancies. Future outlook is characterized by anticipated label extensions, pipeline maturation, and reimbursement shifts as payers recognize the value of targeted disruption of oncogenic and progeroid pathways. Download the FTase Inhibitor Market report to understand which factors are driving the therapeutic market @ FTase Inhibitor Market Trends. FTase Inhibitors Targeted Patient Pool FTase inhibitors address indications such as progeroid laminopathies and head and neck squamous cell carcinoma. Epidemiology segmentation reveals that Hutchinson-Gilford Progeria Syndrome occurs in approximately 1 in 4 million live births, yielding around 400 affected children and young adults globally. Conversely, HNSCC accounts for roughly 890,000 new cases and 450,000 deaths annually worldwide. The total eligible patient pool for FTase inhibitors thus spans ultra-rare genetic disease patients and a subset of HRAS-mutant HNSCC. Real-world treated cases remain limited in progeria due to recent approvals, whereas oncology uptake is emerging in biomarker-enriched cohorts. Geographic segmentation shows the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan as primary markets, with forecasted growth over the 2020–2034 period driven by regulatory approvals, improved diagnostics, and expanded trial enrollment. Discover evolving trends in the FTase Inhibitor patient pool forecasts @ FTase Inhibitor Patient Pool Analysis. Key FTase Inhibitors Companies and Treatment Market The FTase inhibitors treatment landscape is anchored by ZOKINVY (lonafarnib), the first FDA-approved therapy for HGPS and processing-deficient progeroid laminopathies, now commercialized by Sentynl Therapeutics. Current treatment options for progeria are limited to lonafarnib, supplemented by supportive care measures. In oncology, no FTase inhibitor is yet approved, but tipifarnib (Kura Oncology) is in late-stage trials for HRAS-mutant HNSCC, both as monotherapy and in combination with alpelisib. Key FTase Inhibitors companies include Sentynl Therapeutics (ZOKINVY), Kura Oncology (tipifarnib), and strategic collaborators like Novartis (alpelisib combinations) and AnGes Inc. (Japan licensing). Market positioning for FTase inhibitors hinges on their unique mechanism of action, blocking prenylation to impair oncogenic signaling and progerin accumulation. Development milestones encompass ZOKINVY's 2020 FDA approval, its January 2024 Japanese approval, and its May 2024 acquisition by Sentynl. Kura Oncology's tipifarnib recently reported promising Phase II responses in HRAS-driven cohorts, earning Breakthrough Therapy Designation in select indications. Commercial arrangements include licensing of lonafarnib in Asia and co-development agreements for oncology combinations, underscoring the collaborative strategies propelling the FTase inhibitors market forward. Delve deeper into the major and specialised companies in the FTase Inhibitor market @ FTase Inhibitor Competitive Landscape. Conclusion The FTase inhibitors market is at an inflection point, transitioning from a rare-disease focus to broader oncology applications. With established clinical benefits, a robust pipeline, and strategic partnerships, FTase inhibitors are set to redefine treatment paradigms for progeroid disorders and HRAS-driven cancers through 2034 and beyond. Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary of FTase Inhibitor 4. Key Events 5. FTase Inhibitor Epidemiology Market Forecast Methodology 6. FTase Inhibitor Market Overview at a Glance in the 7MM 7. FTase Inhibitor: Background and Overview 8. Epidemiology and FTase Inhibitor Patient Population in Different Indications 9. FTase Inhibitor Target Patient Pool 10. FTase Inhibitor Marketed Therapies 11. FTase Inhibitor Emerging Therapies 12. FTase Inhibitor: Seven Major Market Analysis 13. FTase Inhibitor SWOT Analysis 14. KOL Views 15. FTase Inhibitor Unmet Needs 16. Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Business Insider
10-08-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Globus Medical (GMED) and BioMarin Pharmaceutical (BMRN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kura Oncology (KURA – Research Report), Globus Medical (GMED – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kura Oncology (KURA) Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Kura Oncology on August 8 and set a price target of $27.00. The company's shares closed last Friday at $5.54. According to Zemansky is a 4-star analyst with an average return of 7.4% and a 52.1% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Acumen Pharmaceuticals, and Syndax Pharmaceuticals. Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $25.78, a 352.3% upside from current levels. In a report issued on August 7, LifeSci Capital also maintained a Buy rating on the stock with a $24.00 price target. Globus Medical (GMED) In a report issued on August 8, Craig Bijou from Bank of America Securities reiterated a Hold rating on Globus Medical, with a price target of $65.00. The company's shares closed last Friday at $58.65. According to Bijou is a 3-star analyst with an average return of 1.0% and a 43.9% success rate. Bijou covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Bausch + Lomb Corporation, and Merit Medical Systems. Currently, the analyst consensus on Globus Medical is a Moderate Buy with an average price target of $82.90, implying a 48.0% upside from current levels. In a report issued on August 8, Needham also maintained a Hold rating on the stock. BioMarin Pharmaceutical (BMRN) Bank of America Securities analyst Jason Gerberry maintained a Buy rating on BioMarin Pharmaceutical on August 8 and set a price target of $103.00. The company's shares closed last Friday at $57.33. According to Gerberry is a 3-star analyst with an average return of 2.3% and a 49.5% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Amphastar Pharmaceuticals, and Tarsus Pharmaceuticals. Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $97.95, which is a 65.1% upside from current levels. In a report issued on July 28, Piper Sandler also maintained a Buy rating on the stock with a $122.00 price target.
Yahoo
10-08-2025
- Business
- Yahoo
Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Have Been Cutting Their Estimates
Explore Kura Oncology's Fair Values from the Community and select yours The analysts might have been a bit too bullish on Kura Oncology, Inc. (NASDAQ:KURA), given that the company fell short of expectations when it released its second-quarter results last week. It was not a great statutory result, with revenues coming in 76% lower than the analysts predicted. Unsurprisingly, earnings also fell seriously short of forecasts, turning into a per-share loss of US$0.75. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Taking into account the latest results, the most recent consensus for Kura Oncology from 14 analysts is for revenues of US$129.4m in 2025. If met, it would imply a huge 55% increase on its revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 22% to US$1.78. Before this earnings announcement, the analysts had been modelling revenues of US$149.9m and losses of US$1.64 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, withthe analysts making a serious cut to their revenue outlook while also expecting losses per share to increase. View our latest analysis for Kura Oncology There was no major change to the consensus price target of US$25.75, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Kura Oncology analyst has a price target of US$40.00 per share, while the most pessimistic values it at US$8.00. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Kura Oncology's past performance and to peers in the same industry. The analysts are definitely expecting Kura Oncology's growth to accelerate, with the forecast 142% annualised growth to the end of 2025 ranking favourably alongside historical growth of 100% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 19% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Kura Oncology is expected to grow much faster than its industry. The Bottom Line The most important thing to take away is that the analysts increased their loss per share estimates for next year. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Kura Oncology analysts - going out to 2027, and you can see them free on our platform here. Before you take the next step you should know about the 1 warning sign for Kura Oncology that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
CNBC
11-06-2025
- Business
- CNBC
Lightning Round: 'Wait and see situation' with Papa John's, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Joby Aviation, Arm Holdings, Kura Oncology, and Papa John's.
Yahoo
06-06-2025
- Business
- Yahoo
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the 'Company') (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the 'Compensation Committee') granted inducement awards consisting of nonstatutory stock options to purchase 79,200 shares of common stock to five (5) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price equal to $6.30 per share, the Company's closing sales price on June 2, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company's 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration ('FDA') for the treatment of relapsed/refractory ('R/R') NPM1-mutant acute myeloid leukemia ('AML'). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA's acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn. Contacts Investors:Patti BankManaging Director(415) Media:media@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
